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Abstract We used whole-genome exon-targeted oligonucleo-
tide array comparative genomic hybridization (array CGH) in a
cohort of 256 patients with developmental delay (DD)/
intellectual disability (ID) with or without dysmorphic features,
additional neurodevelopmental abnormalities, and/or congeni-
tal malformations. In 69 patients, we identified 84 non-
polymorphic copy-number variants, among which 41 are
known to be clinically relevant, including two recently de-
scribed deletions, 4q21.21q21.22 and 17q24.2. Chromosomal
microarray analysis revealed also 15 potentially pathogenic
changes, including three rare deletions, 5q35.3, 10q21.3, and
13q12.11. Additionally, we found 28 copy-number variants of
unknown clinical significance. Our results further support the
notion that copy-number variants significantly contribute to the
genetic etiology of DD/ID and emphasize the efficacy of the
detection of novel candidate genes for neurodevelopmental
disorders by whole-genome array CGH.
Keywords Copy-number variation .Microdeletion .
Microduplication . Chromosomalmicroarray analysis
Introduction
Developmental delay (DD)/intellectual disability (ID), char-
acterized by a significant impairment of cognitive and adap-
tive functions, affects 1–3 % of the general population (Harris
2006; Maulik et al. 2011), with the majority of affected
individuals remaining without proper diagnosis (Rauch et al.
2006; Pfundt and Veltman 2012). The etiology of DD/ID is
heterogeneous, with both genetic and environmental contri-
bution (Grayton et al. 2012). In addition to Mendelian DD/ID,
one of the most common causes are microscopically visible
chromosomal aberrations and submicroscopic copy-
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number variants (CNVs) (Morrow 2010; Regier et al. 2010).
A high-resolution G-banded karyotype reveals chromosome
abnormalities in 3–5 % of patients with idiopathic DD/ID
(Shevell et al. 2003), and molecular cytogenetic analyses,
e.g., fluorescent in situ hybridization (FISH) in the
subtelomeric regions, provides diagnosis in an additional 3–
6 % of cases (Koolen et al. 2004; Ravnan et al. 2006). In the
past few years, application of chromosomal microarray anal-
ysis (CMA), including array comparative genomic hybridiza-
tion (array CGH) and single-nucleotide polymorphism (SNP)
arrays, has revolutionized the clinical diagnostics in patients
with idiopathic DD/ID (Cooper et al. 2011; Kaminsky et al.
2011; Girirajan et al. 2012). Recently, it has been proven that
CMA should be a first-tier clinical diagnostic test for individ-
uals with DD, ID, autism spectrum disorders, and dysmorphic
features (Miller et al. 2010; Battaglia et al. 2013). Clinically
relevant CNVs, ranging in size from megabases to kilobases
(Rodriguez-Revenga et al. 2007), have been detected in ∼10–
20 % of cases (Menten et al. 2006; Stankiewicz and Beaudet
2007; Koolen et al. 2009) and have led to the identification of
several novel microdeletions and microduplications associat-
ed with DD/ID (Slavotinek 2008; Vissers and Stankiewicz
2012), e.g., involving chromosomes 1q41q42, 9q22.3,
15q13.3, 15q24, 16p11.2, and 17q21.31 (Koolen et al. 2006;
Redon et al. 2006; Sharp et al. 2006; Shaw-Smith et al. 2006;
Ballif et al. 2007; Shaffer et al. 2007; Sharp et al. 2007, 2008).
Refinement of the critical region of a known syndrome by the
identification of atypical deletion (Cooper et al. 2011) may
facilitate the detection of a dosage-sensitive gene(s) related to
ID (Vissers et al. 2010); however, there are many CNVs for
which the clinical significance may still remain unknown
(Rodriguez-Revenga et al. 2007). Recently, clinical and bio-
logical interpretation of those variants and their genotype–
phenotype correlation enabled the generation of a human
genome morbid map (Cooper et al. 2011).
Here, we present the results of the application of
genome-wide array CGH in a cohort of 256 patients with
DD/ID, dysmorphic features, congenital malformations, or
additional neurodevelopmental abnormalities. We identified
84 non-polymorphic CNVs in 69 patients, including 41
clinically relevant CNVs, 15 potentially novel pathogenic
genetic loci for DD/ID, and, additionally, 28 CNVs of




We studied 256 patients with DD/ID, dysmorphic features,
congenital malformations, or additional neurodevelopmental
abnormalities. Among them, 234 patients had normal GTG
banding analysis with at least 550-band resolution and 46
patients had a negative fragile X testing.
We provide a detailed clinical description of five patients
(Supplementary material) and discuss their genotype–pheno-
type correlations. Patients 23 and 34 have de novo CNVs that
we believe are pathogenic, and patients 45, 50, and 51 have
potentially pathogenic CNVs.
DNA isolation
Genomic DNA was extracted from peripheral blood cells
using a Puregene DNA Blood Kit (Qiagen, Gentra Systems,
Minneapolis, MN), according to the manufacturer’s protocol.
The reference DNA samples were obtained from phenotypi-
cally normal male and female controls.
Array CGH
Custom-designed exon-targeted clinical array CGH was per-
formed using 105K V7.4 and 180K V8.0 or V8.1 microarrays
designed in the Medical Genetics Laboratories at Baylor
College of Medicine (BCM) (http://www.bcm.edu/geneticlabs/
cma/tables.html) in cooperation with the Department ofMedical
Genetics at the Institute of Mother and Child and manufactured
by Agilent Technologies (Santa Clara, CA). V7.4 consisted of
105,000 oligonucleotides having genome-wide coverage with
an average resolution of 30 kb, while V8.0 and V8.1 OLIGO
(180K) arrays have genome-wide coverage as well as exon
coverage for over 1,700 known or candidate disease genes with
an average of 4.2 oligos per exon and intronic gaps no larger
than 10 kb (Boone et al. 2010). The microarray used in this
study does not contain SNP probes and it does not detect regions
of absence of heterozygosity (AOH). The results of studies
using the updated version of this array were recently published
by the BCM (Wiszniewska et al. 2013). Digestion, labeling, and
hybridization were performed following the manufacturer’s in-
structions. The BCM web-based software platform and the
homebrew IMiD-web2py software were used for chromosomal
microarray analysis. All genomic coordinates are based on the
March 2006 assembly of the reference genome (NCBI36/hg18).
To verify the rearrangements identified by array CGH, depend-
ing on CNVs size, we used GTG banding and FISH. When
available, blood samples were obtained from patients’ parents,
and CNV inheritance was investigated.
Karyotype analysis
GTG banding analysis was performed according to the stan-
dard protocol in peripheral blood lymphocytes. The meta-
phases with 550-band resolution were analyzed in cases with
CNVs 5 Mb or greater in size.
126 J Appl Genetics (2014) 55:125–144
Fluorescent in situ hybridization (FISH) analysis
Confirmatory FISH experiments were performed to verify the
presence of CNVs ranging in size from 150 kb to 5 Mb. FISH
analyses were performed by standard procedures in
phytohemagglutinin-stimulated peripheral blood lymphocytes
using probes derived from bacterial artificial chromosomes.
When available, blood samples were obtained from the pa-
tient’s parents and the origin of the identified CNVs was
studied using FISH with the same probes.
Results
A total of 84 non-polymorphic CNVs were found in 69 of 256
patients studied. We divided the detected CNVs into three
groups. The first group contains 41 CNVs considered to be
clinically relevant (i.e., pathogenic for DD/ID) (Table 1). This
group includes 18 imbalances greater than 5 Mb in size
identified in 17 patients (not seen in standard cytogenetic
studies) and 23 submicroscopic CNVs. In three cases, two
pathogenic CNVs were detected: patient 9 had an unbalanced
translocation der(10)t(10;20)(q26.2;q13.33); patient 10 had a
terminal duplication dup(11)(p15) and a terminal deletion
del(11)(q24), most likely a recombination product of a
pericentromeric inversion inv(11)(p15q24); and patient 12
had a large 15q13.3q14 deletion in addition to the well-
known recurrent microdeletion 16p13.11. We also identified
two mosaic trisomies of chromosome 9 (pt 15 and pt 16) and
monosomy of chromosome 7 in a 1-year-old patient (pt 17)
with DD and combined immunodeficiency. Among 23 sub-
microscopic CNVs, we identified known recurrent rearrange-
ments, e.g., deletions 15q11.2, 16p13.3, 17q11.2, and
17q21.31 and different-sized non-recurrent CNVs, e.g., dele-
tions 1p36.31p36.33, 1q43q44, 5q14.3, 6q25, and 10q24.32,
as well as duplications 3p21.1 and 19p13.3. In this group, we
also identified two recently described microdeletions at chro-
mosomes 4q21 and 17q24.2.
The second group consists of 15 CNVs potentially patho-
genic for DD/ID (Table 2). In three cases, we identified
rare CNVs: two de novo deletions at 13q12.11 and 5q35.3,
and in one patient, a deletion at 10q21.3 and a duplication at
19p13.42p13.43.
In the third group, we classified 28 deletions and duplica-
tions of unknown clinical significance, some of which are
likely non-pathogenic for DD/ID (Tables 1, 2, and 3). We
found four individuals with BP1/BP2 duplication at 15q11.2
that is frequently found in the general population and consid-
ered as a benign event.
Moreover, we present the cumulative data of the studied
cohort (Table 4), including patients with normal array CGH
results (Supplementary Table 1).
Discussion
To determine the phenotypic consequences of the 84 identi-
fied non-polymorphic CNVs, we considered their type
(deletion vs. duplication), size, gene content, inheritance pat-
tern, and the available clinical or genomic database informa-
tion. We classified them into three groups: 41 (16.0 %) known
well-recognized causative for DD/ID, 15 (5.85 %) novel
potentially pathogenic, and 28 (10.9 %) variants of unknown
clinical significance (Tables 1, 2, and 3). The first group
includes CNVs responsible for the well-known diseases and
syndromes or published genomic imbalances that were con-
sidered as clinically relevant for DD/ID. The second group
consists of novel CNVs potentially causative for DD/ID and
includes changes that were not previously reported to be
associated with DD/ID but contain genes that may contribute
to our patients’ phenotypes. Moreover, we compared CNVs
classified as the second group with the publically available
databases. The same or similar sized aberrations were not
found in the Database of Genomic Variants (DGV, http://
projects.tcag.ca/variation/), Database of Chromosomal
Imbalance and Phenotype in Humans Using Ensembl
Resources (DECIPHER, http://decipher.sanger.ac.uk), or the
International Standards for Cytogenomic Arrays database
(ISCA, https://www.iscaconsortium.org). In the third group
of variants of unknown clinical significance, we classified
CNVs that contain genes that were not previously associated
with DD/ID, are frequently found in the general population, or
were inherited from a healthy parent.
From the second group of potentially pathogenic CNVs,
we selected for the detailed description three novel rare,
probably pathogenic, deletions containing candidate genes
that may contribute to the abnormal phenotypes observed in
our patients. Furthermore, in two of those cases (pt 51 and
pt 45), deletions arose de novo that support their potential
pathogenicity.
A de novo ∼250-kb deletion in 13q12.11, encompassing
only two genes, PSPC1 (paraspeckle component 1; MIM
612408) and ZMYM5 (zinc finger, MYM-type 5), was identi-
fied in pt 51 with remarkably delayed psychomotor develop-
ment, muscle hypotonia, unilateral microphtalmia with ptosis,
congenital eye malformation, and facial dysmorphic features
(Fig. 1a, d). Interstitial deletions of 13q12.11 are very rare
(Der Kaloustian et al. 2011; Tanteles et al. 2011). Tanteles et al.
(2011) described a de novo 2.9-Mb 13q12.11 deletion of 19
genes, including PSPC1 and ZMYM5 , in a patient with near
normal development and intellect but with scaphocephaly and
facial dysmorphism. PSPC1 encodes a nucleolar protein that
localizes to punctate subnuclear structures close to splicing
speckles, known as paraspeckles. Paraspeckles may function
in the control of gene expression via an RNA nuclear retention
mechanism. Functionally, PSPC1 was proposed to participate
in the regulation of transcription (Passon et al. 2011). ZMYM5
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52 M 14 Karyotype 1q21.1 (144,124,745–
144,452,014)x3
0.327 –/– unknown Moderate ID, speech delay, articulation defects,
learning difficulties, and EEG abnormalities;
dysmorphic features: hypertelorism, large
ears, protruding ears, deep philtrum, high
forehead, ptosis, prognathism, feet
abnormalities, partial cutaneous syndactyly of
fingers 2 and 3, and obesity since early
childhood
53 F 7 Karyotype 5q14.2 (82,442,763–
82,552,656)x1
0.109 FISH/FISH mat Moderate ID and behavioral abnormalities;
dysmorphic features: high forehead, bilateral
epicanthus, dysplastic, prominent and low-set
ears with up-lift ear lobule, broad nasal bridge,
thick helix, upturned nasal tip, anteverted nares,
prognathism, strabismus deep set eyes, and
clinodactyly of Vth digits
54 M 7 Karyotype 7p15.3 (23,684,650–
23,791,776)x1
0.107 FISH/FISH pat Delayed psychomotor development,
moderate ID, speech delay, hyperactivity,
and learning difficulties; dysmorphic
features: up-slanting palpebral fissures,
high palate, cleft soft palate, strabismus,
neonatal feeding difficulties, and scoliosis;
suspicion of Raynaud’s phenomenon






pat Mildly delayed motor development, moderate
ID, significant delay in speech development,
behavioral abnormalities with aggression,
irritability, and short attention span, muscle
hypotonia, extreme obesity, hypogenitalism,
and ectropion of lower eyelids





0.382 FISH/FISH pat Delayed psychomotor development, muscular
hypotonia, epilepsy, postnatal short stature
(−3.87 SD), postnatal underweight
(−4.83 SD), Pierre Robin sequence,
neonatal feeding difficulties, absent suck,
neonatal recurrent vomiting; dysmorphic
features: high forehead, down-slanting
palpebral fissures, hypertelorism, low-set
ears, broad nasal bridge, strabismus, and
club feet; family history: father: healthy






de novo Delayed psychomotor development, severe
ID, postnatal short stature, cardiac
abnormalities (ASD, VSD, PDA), severe
sensorineural deafness hypothyroidism;
dysmorphic features: facial asymmetry,
hypotelorism, ptosis, long, hooked nose,
cleft palate, micrognathia, neck webbing,
radioulnar synostosis, myopia, accessory
spleen, family history: 1× stillbirth without
congenital malformations, 1× miscarriage
(first trimester of gestation)
58 M 2 Karyotype 12q21.1 (70,966,697–
71,222,382)x1
0.255 FISH/FISH pat Delayed psychomotor development, absent
speech (inarticulate, single sounds), in the
neonatal/infantile period of life: limbs
hypertonia/axial hypotonia, seizures,
pre-/postnatal microcephaly: (−5.65 SD),
epilepsy, brain MRI: suspicion of septo-optic
dysplasia, polymicrogyria, schizencephaly,
and subependymal heterotopy; dysmorphic
features: down-slanting palpebral fissures,














genitourinary abnormalities: extrarenal pelvis
(left kidney) and optic disc hypoplasia








mat Delayed psychomotor development, profound
ID, absent speech, neonatal and infantile
feeding problems, muscular limbs hypertonia,
seizures, drug-resistant epilepsy, pre- and
postnatal microcephaly, stereotyped
movements; dysmorphic features
brachycephaly, micrognathia, protruding ears,
open mouth appearance, full cheeks,
abnormal brain MRI: temporal cortical
atrophy (right), scoliosis, cryptorchidism,
nystagmus, hematologic abnormalities, and
unexplained transient highly elevated
leukocytosis (30,000/ml); family history:
proband’s sister: very similar clinical
symptoms suggestive for unexplained
encephalopathy with drug-resistant epilepsy
60 M 15 Karyotype 15q11.2 (19,924,765–
20,642,621)x3
0.717 –/– unknown Delayed psychomotor development, profound
ID, absent speech, stereotyped movements,
neonatal/infantile feeding difficulties,
poor suck, poor weight gain, postnatal
failure to thrive, pectus excavatum,
chondro-osseous exostoses on the
lower limbs, strabismus, and secondary
osteoporosis (hypercalciuria)
61 M 10 Karyotype 15q11.2 (20,006,102–
20,642,621)x3
0.636 –/– unknown Delayed psychomotor development, moderate
ID, speech delay, articulation defect, learning
difficulties, vertebral and rib anomalies, short
neck, postnatal short stature (relatively short
lower limbs), postnatal underweight, heart
defect (ASD, VSD), and strabismus; family
history: 1× miscarriage in the mothers’
gestational history; features of Jarcho–Levin-
like syndrome




0.139 FISH/FISH mat Delayed psychomotor development, moderate
ID, neonatal/infantile feeding difficulties,
joints laxity, pectus excavatus, strabismus,
and heart defect (VSD); dysmorphic
features: Kabuki-like makeup syndrome,
ectropion of eyelids, wide palpebral fissures,
epicanthic folds, prominent ears, flat
philtrum, and fetal finger pads
63 F 14 Karyotype/FraX 16q23.1 (77,445,915–
78,190,209)x3
0.744 –/aCGH not mat Mild/moderate ID, mild dysmorphic features,
hypertelorism, high forehead transverse
palmar crease, and low posterior hairline







1.123 –/– unknown Severe ID, absent speech, stereotyped
movements, breath holding, postnatal
microcephaly, inability to walk
independently, rash of upper limbs;
dysmorphic features, short philtrum, uplift
earlobes, thick and sparse eyebrows, flat
facial profile, protruding tongue, exotropia,
and gum hypertrophy; family history: 1×
miscarriage; clinical diagnosis of Rett
syndrome, molecular confirmation of
MECP2 mutation
J Appl Genetics (2014) 55:125–144 137
belongs to the zinc finger MYM-type family and probably has
molecular functions, such as metal ion binding or zinc ion
binding (Pastorcic and Das 2007). Although the phenotype–
genotype correlation remains unclear and one smaller deletion
within this region was reported in the control group (DGV;
nsv455826) (Itsara et al. 2009), we propose that the identified
de novo 13q12.11 deletion could contribute to the clinical


















0.427 –/– unknown Mild ID, speech delay, Postnatal microcephaly,
abnormal brain MRI: arachnoid cyst and
cerebellar vermis hypoplasia, EEG
abnormalities, heart defect: tetralogy of
Fallot (TOF), unilateral inguinal hernia, and
vesicoureteral reflux; dysmorphic features:
hypertelorism, telecanthus, short philtrum,
downturned corners of the mouth, and thin
lips
66 F 4 – Xp22 (502,226–
1,744,236)x3
1.242 –/– unknown Delayed psychomotor development, severe
ID, speech delay (only single words), and
autistic spectrum behavior; dysmorphic
features: almond-shaped eyes, short
philtrum, downturned corners of the
mouth, prominent nasal tip, and proximal
placement of the thumbs; family history:
1× miscarriage in the mother






0.194 –/aCGH not mat Profound ID and absent speech (only single
words); dysmorphic features: deep-set eyes,
straight supraorbital ridges, postnatal
microcephaly, behavior abnormalities:
aggression, autoaggression, stereotyped
movements, obesity, and small hands and
feet; family history: mother: mild ID





0.216 –/aCGH pat Delayed psychomotor development, speech
delay (only single words), relative postnatal
microcephaly (−2.05 SD), feeding
difficulties, absent suck, distal
arthrogryposis, (dimples over the
interphalangeal joints), and premature
thelarche; dysmorphic features: up-slanting
palpebral fissures, long philtrum,
downturned corners of the mouth, metopic
ridge, and strabismus





0.056 –/– unknown Profound ID, absent speech, behavioral
abnormalities (hyperactivity, aggression),
autism spectrum symptoms, muscular
hypotonia, microcephaly, epilepsy,
brachydactyly, alopecia areata, thin skin
with hyperpigmentation in the perioral and
periorbital regions; family history: stillbirth
newborn from the mothers’ first pregnancy
died after birth (IUGR without congenital
malformations) and 2× miscarriages at the
first trimester of the mother’s pregnancies
DD, developmental delay; ID, intellectual disability; SD, standard deviation; ASD, atrial septal defect; VSD, ventricular septal defect; PDA, patent
ductus arteriosus; IUGR, intrauterine growth restriction; MRI, magnetic resonance imaging; EEG, electroencephalography; mat, maternal; pat, paternal
The total number of CNVs of unknown clinical significance includes CNVs in Table 3 and the additional changes listed under Tables 1, 2, and 3
a Patient 55 with a karyotype 46,XY,t(2;11)(q21;q23) has an additional 0.754-Mb deletion at 2q22.11 inherited from the normal mother [2q22.1
(138,045,798–138,799,860)x1 mat]
138 J Appl Genetics (2014) 55:125–144
In a girl (pt 45) with an atypical autism spectrum disorder
and moderate mental impairment with absent expressive
speech development, we detected a de novo ∼720-kb deletion
at 5q35.3 that partially overlaps a common-sized ∼1.9-Mb
recurrent deletion found in patients with Sotos syndrome
(MIM 117550) but leaves the dosage-sensitive NSD1 gene
(set domain protein 1; MIM 606681) intact (Fig. 1b, e). Rauch
et al. (2003) described a novel 5q35.3 subtelomeric deletion
distally adjacent to the Sotos common deletion region, and
characterized by pronounced muscular hypotonia, postnatal
short stature, and bell-shaped thorax with pectus carinatum.
The deletion identified in our patient harbors 15 genes, includ-
ingDBN1 , B4GALT7 , PROP1 , andNHP2 .DBN1 (drebrin E;
MIM 126660) is a cytoplasmic actin-binding protein thought
to play a role in neuronal growth and dendritic spine formation.
It is a member of the drebrin family of proteins that are
developmentally regulated in the brain. Shim and Lubec
(2002) and Dun and Chilton (2010) suggested that a decreased
amount of drebrin may lead to loss of spine plasticity and
impaired dendritic arborization, which may underlie cognitive
dysfunction. PROP1 (paired-like homeodomain transcription
factor; MIM 601538) has both DNA-binding and transcrip-
tional activation ability. Its expression leads to ontogenesis of
pituitary gonadotropes, as well as somatotropes, lactotropes,
and caudomedial thyrotropes. Heterozygous mutations in
PROP1 have been reported in patients with pituitary hormone
deficiency-2 (CPHD2;MIM262600). Homozygousmutations
of B4GALT7 (galactosyltransferase I; MIM 604327) have
been described in patients with the progeroid form of Ehlers–
Danlos syndrome (MIM 130070) characterized by an aged
appearance, DD, short stature, craniofacial disproportion, gen-
eralized osteopenia, defective wound healing, hypermobile
joints, hypotonic muscles, and loose but elastic skin
(Okajima et al. 1999). Lastly, homozygous or compound het-
erozygous mutations in the NHP2 gene (nucleolar protein
family A, member 2; MIM 606470) have been found in
individuals with autosomal recessive dyskeratosis congenita-
2 (DKCB2; MIM 613987). Given that the 5q35.3 deletion in
our patient arose de novo and the fact that the deleted genes are
associated with neurodevelopmental disorders and play a role
in neuronal processes, we suggest that the identified CNV is
potentially pathogenic for the described clinical features.
In patient 50 with short stature, moderate ID, and his-
tory of Hirschsprung disease and congenital heart defect,
we found a rare ∼1.4-Mb deletion in 10q21.3 encompassing
16 genes (Fig. 1c, f) and a small ∼400-kb duplication in
19q13.42q13.43. Deletions in 10q21.3 have never been re-
ported in patients with DD/ID, thus, it is challenging to assess
its clinical pathogenicity. However, the size and gene-rich
content suggest that the 10q21.3 deletion could be pathogenic.
Analysis of the maternal sample revealed normal result; un-
fortunately, the paternal sample was unavailable. Five genes,
including SIRT1 (sirtuin 1; MIM 604479), DNA2 (DNA
replication helicase 2; MIM 601810), TET1 (Tet oncogene
family, member 1; MIM 607790), CCAR1 (cell division
cycle and apoptosis regulator 1; MIM 612569), and DDX50
Table 4 Summary of the studied cohort of 256 patients with DD/ID












DD (age 1–6 years) 74 17 (22.9 %) 12 (16.2 %) 2 4 1
Mild ID 32 11 (34.3 %) 6 (18.7 %) 5 2 2
Age <12 years 22 7 4 3 1 –
Age 13–18 years 8 4 2 2 1 –
Age >18 years 2 – – – – –
Moderate ID 57 18 (31.5 %) 11 (19.2 %) 2 10 5
Age <12 years 35 13 8 – 8 –
Age 13–18 years 20 4 2 2 2 –
Age >18 years 2 1 1 – – –
Severe ID 32 10 (31.2 %) 5 (15.6 %) 2 8 4
Age <12 years 25 9 4 2 8 –
Age 13–18 years 7 1 1 – – –
Age >18 years – – – – – –
Profound ID 61 13 (21.3 %) 7 (11.4 %) 4 4 2
Age <12 years 35 7 5 2 1 –
Age 13–18 years 19 6 2 2 3 –
Age >18 years 7 – – – – –
J Appl Genetics (2014) 55:125–144 139
(dead/h box 50; MIM 610373) represent dosage-sensitive
genes (Huang et al. 2010); however, to date, no phenotype
associated with haploinsufficiency of any of these genes has
been reported. In addition, SLC25A16 (solute carrier family
25, member 16; MIM 139080) encodes a protein that is
localized in the inner membrane and facilitates the rapid
transport and exchange of molecules between the cytosol
and the mitochondrial matrix space. This gene was proposed
to play a role in Graves disease (MIM 275000). Of note, other
SLC family genes, SLC9A9 (MIM 608396), SLC6A4 (MIM
182138), and SLC25A12 (MIM 603667), are causative for
autism. Other genes mapping in the deleted region, including
DNAJC12 (MIM 606060), HERC4 (MIM 609248), PBLD
(MIM 612189), HNRNPH3 (MIM 602324), RUFY2 (MIM
610328), STOX1 (MIM 609397), and CTNNA3 (MIM
607667), have been linked to late-onset Alzheimer’s disease
(AD6; MIM 605526). CTNNA3 , encoding the alpha-3 caten-
in and likely responsible for the formation of stretch-resistant
cell–cell adhesion complexes (Weiss et al. 2009), has been
associated with late-onset Alzheimer’s disease in females
(Miyashita et al. 2007). Bradley et al. (2010) suggested that,
if CTNNA3 is involved in Alzheimer’s disease, it is not
through a loss-of-function mechanism. Moreover, we suggest
that CTNNA3 and/or MYPN (myopalladin, MIM 608517),
deleted 10q21 region, can be responsible for the congenital
heart defect observed in our patient. CTNNA3 has been
considered as a candidate for the form of dilated cardiomy-
opathy linked to 10q21q23 (CMD1C; 601493) because of its
high expression in the heart. MYPN is a component of the
sarcomere that tethers nebulette in cardiac muscle to alpha-
actinin andmay play signaling roles in targeting and orienting
nebulin to the Z line during sarcomere assembly. The
associated ∼400-kb duplication in 19q13.42q13.43 harbors
seven genes (NLRP8 ; MIM 609659, NLRP5 ; MIM 609658,
ZNF787 , ZNF444 ; MIM 607874, GALP ; MIM 611178,
ZSCAN5B , and ZSCAN5A ), none of which represent a
Fig. 1 Results of array CGH analyses: a patient 51, showing a de novo
∼250-kb deletion in 13q12.11; b patient 45, demonstrating a de novo
∼720-kb deletion at 5q35.3; and c patient 50, showing a rare ∼1.4-Mb
deletion in 10q21.3. The red dots denote the deleted region. Gene content
in the deleted region on: d chromosome 13q12.11; e chromosome 5q35.3
(compared with the critical region of the Sotos syndrome and 5q35.3
subtelomeric deletion syndrome); and f chromosome 10q21.3 (UCSC
genome browser, http://genome.ucsc.edu/)
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dosage-sensitive gene. Therefore, we classified this duplica-
tion as a variant of unknown clinical significance.
Among our 41 CNVs known as being pathogenic for DD/
ID, we elected to discuss two deletions, 4q21 and 17q24.2,
which have been described recently as responsible for
microdeletion syndromes associated with DD/ID. Moreover,
in those patients (pt 23 and pt 34), previously performed
genetic tests were negative (Table 1), which demonstrates
the usefulness of array CGH as a great tool for identifying
the etiology of idiopathic DD/ID.
A de novo ∼3.1-Mb deletion at 4q21.21q21.22 identified in
patient 23 overlaps CNVs reported in the literature (Harada
et al. 2002; Friedman et al. 2006; Bonnet et al. 2010; Lipska
et al. 2011). Bonnet et al. (2010) defined a 1.37-Mb critical
region containing five genes, PRKG2 (MIM 601591),
RASGEF1B (MIM 614532), HNRNPD (MIM 601324),
HNRPDL (MIM 607137), and ENOPH1 , and proposed that
PRKG2 and RASGEF1B are the best candidate genes respon-
sible for the 4q21 deletion syndrome (MIM 613509) charac-
terized by severe ID, lack of speech, hypotonia, significant
growth restriction, and distinctive facial features. Our patient
enables a better delineation of a novel 4q21 microdeletion
syndrome and further supports the proposed contribution of
haploinsufficiency of PRKG2 and RASGEF1B .
We also identified a de novo ∼1.9-Mb deletion at 17q24.2
(pt 34), harboring the smallest region of overlap of four
deletions recently reported byVergult et al. (2012). The shared
clinical features include ID, speech delay, truncal obesity, and
similar facial gestalt. The ∼713-kb critical region contains five
genes, including PRKCA (MIM 176960), a cluster of three
CACNG genes encoding the gamma subunit of a voltage-
dependent calcium channel, CACNG5 (MIM 606405),
CACNG4 (MIM 606404), CACNG1 (MIM 114209), and
HELZ (MIM 606699). The PRKCA gene encodes the
serine- and threonine-specific protein kinase C alpha that
plays an important role in many different cellular processes
and is the most important candidate gene for many of the
observed clinical features. Investigations ofmore patients with
17q24.2 deletions would strengthen the genotype–phenotype
correlation in this newly reported microdeletion syndrome.
Moreover, in two patients (pt 15 and pt 16) with normal
standard cytogenetic results, we detected chromosomal aneu-
ploidy in the form of a mosaic trisomy 9 using array CGH.
In both cases, chromosomal mosaicism was confirmed by
retrospective GTG banding analysis that revealed low-level
mosaicism for trisomy 9 of 12.5 % and 8 %, respectively.
Additionally, in patient 17 with DD and combined immuno-
deficiency and normal karyotype, we found a monoso-
my of chromosome 7 in his peripheral blood leukocytes.
Chromosome 7 monosomy and 7q deletion have been fre-
quently found in patients with myelodysplastic syndrome
(MDS). MDSs are a heterogeneous group of stem cell disor-
ders characterized by ineffective hematopoiesis, dysplastic
changes in bone marrow and peripheral blood, and the risk
of transformation to acute myeloid leukemia (AML) (Cordoba
et al. 2012). We suggest that the identified aberration is
responsible for the phenotypic abnormalities observed in our
patient.
Additionally, our analyses of the DD/ID cohort revealed
patients with more than one clinically relevant CNVs. Apart
from patients 9, 10, and 12 with two pathogenic CNVs, we
identified two patients (pt 39 and pt 46) with two rare poten-
tially pathogenic changes. A complex clinical presentation in
those patients supports a second-hit model, in which the
compound effect of multiple CNVs, including those of un-
known pathogenic significance, contributes to the phenotypic
heterogeneity (Girirajan et al. 2012).
These results further demonstrate that array CGH, in addi-
tion to the identification of CNVs and chromosomal aneu-
ploidies, also enables the detection and estimation of their
low-level mosaicism that may remain undetected by conven-
tional cytogenetic methods (Cheung et al. 2007). Furthermore,
our results support the usefulness of array CGH in the identi-
fication of the aneuploidy of cells under-represented in the
T-cell population missed by routine chromosome analysis.
However, apart from balanced aberrations (e.g., transloca-
tions, inversions), array CGH without SNP oligonucleotides
cannot detect uniparental disomy.
In summary, we found that 69 of 256 patients with DD/ID
carry one or more CNVs, in 38 cases responsible for the
observed clinical features and in 13 patients potentially path-
ogenic for DD/ID. Our results further confirm the usefulness
of array CGH in the detection of pathogenic CNVs in patients
with idiopathic neurodevelopmental disorders.
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